Concurrent hormone and radiation therapy in patients with breast cancer: how does chemotherapy affect treatment?

Bernard Candas, Steeve Couillard, Matthieu Gutman, Claude Labrie, Fernand Labrie, Effect of Combined Treatment with the Pure Antiestrogen EM-800 and Radiotherapy on the Growth of Human ZR-75-1 Breast Cancer Xenografts in Nude Mice Cancer Research. ,vol. 59, pp. 4857- 4863 ,(1999)

Alan E. Wakeling, The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Research and Treatment. ,vol. 25, pp. 1- 9 ,(1993) , 10.1007/BF00662395

Sylvain Gauthier, Brigitte Caron, Julie Cloutier, Yves L. Dory, Alexandre Favre, Denis Larouche, Josée Mailhot, Carl Ouellet, Annette Schwerdtfeger, Gilles Leblanc, Céline Martel, Jacques Simard, Yves Mérand, Alain Bélanger, Claude Labrie, Fernand Labrie, (S)-(+)-4-[7-(2,2-Dimethyl-1-oxopro- poxy)-4-methyl-2-[4-[2-(1-piperidinyl)- ethoxy]phenyl]-2H-1-benzopyran-3-yl]- phenyl 2,2-Dimethylpropanoate (EM-800):  A Highly Potent, Specific, and Orally Active Nonsteroidal Antiestrogen Journal of Medicinal Chemistry. ,vol. 40, pp. 2117- 2122 ,(1997) , 10.1021/JM970095O

Mathieu Gutman, Steeve Couillard, Fernand Labrie, Bernard Candas, Claude Labrie, Effect of treatment sequence with radiotherapy and the antiestrogen EM 800 on the growth of ZR 75 1 human mammary carcinoma in nude mice. International Journal of Cancer. ,vol. 103, pp. 268- 276 ,(2003) , 10.1002/IJC.10803

Cyrus Chargari, Robert Alain Toillon, Dhara MacDermed, Pierre Castadot, Nicolas Magné, Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale? Lancet Oncology. ,vol. 10, pp. 53- 60 ,(2009) , 10.1016/S1470-2045(08)70333-4

Fernand Labrie, Pierre Champagne, Claude Labrie, Jean Roy, Jacques Laverdière, Louise Provencher, Martin Potvin, Yvan Drolet, Michael Pollak, Lawrence Panasci, Bernard L'Espérance, Jean Dufresne, Jean Latreille, Jean Robert, Benoît Samson, Jacques Jolivet, Louise Yelle, Lionel Cusan, Pierre Diamond, Bernard Candas, Activity and Safety of the Antiestrogen EM-800, the Orally Active Precursor of Acolbifene, in Tamoxifen-Resistant Breast Cancer Journal of Clinical Oncology. ,vol. 22, pp. 864- 871 ,(2004) , 10.1200/JCO.2004.05.122